Literature DB >> 12456495

PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4.

Ulrich Kintscher1, Christopher Lyon, Shu Wakino, Dennis Bruemmer, Xu Feng, Stephan Goetze, Kristof Graf, Aristidis Moustakas, Bart Staels, Eckart Fleck, Willa A Hsueh, Ronald E Law.   

Abstract

Integrins play an important role in vascular smooth muscle cell (VSMC) migration, a crucial event in the development of restenosis and atherosclerosis. Transforming growth factor-beta (TGF-beta) is highly expressed in restenotic and atherosclerotic lesions, and known to induce integrin expression. Peroxisome proliferator-activated receptor alpha (PPARalpha), a member of the nuclear receptor superfamily, regulates gene expression in a variety of vascular cells. We investigated the effects of PPARalpha ligands on TGF-beta-induced beta3 and beta5 integrin expression and potential interaction between PPARalpha and TGF-beta signaling. PPARalpha ligands WY-14643 (100 micromol/L) and 5,8,11,14-eicosatetranoic acid (ETYA, 50 micromol/L) inhibited TGF-beta-induced beta5 integrin protein expression by 72+/-6.8% and 73+/-7.1%, respectively (both P<0.05). TGF-beta-stimulated beta3 integrin expression was not affected by PPARalpha ligands. Both PPARalpha ligands also suppressed TGF-beta-induced beta5 integrin mRNA levels. PPARalpha ligands inhibited TGF-beta-inducible transcription of beta5 integrin by an interaction with a TGF-beta response element between nucleotides -63 and -44, which contains a Sp1/Sp3 transcription factor binding site. Nuclear complexes binding to the TGF-beta response region contained Sp1/Sp3 and TGF-beta-regulated Smad 2, 3, and 4 transcription factors. TGF-beta-stimulated Sp1/Smad4 nuclear complex formation was inhibited by WY-14643 and ETYA with a parallel induction of PPARalpha/Smad4 interactions. However, in vitro pull-down experiments failed to demonstrate direct binding between PPARalpha/Smad4. Both PPARalpha ligands blocked PDGF-directed migration of TGF-beta-pretreated VSMCs, a process mediated, in part, by beta5 integrins. The present study demonstrates that PPARalpha activators inhibit TGF-beta-induced beta5 integrin transcription in VSMCs through a novel indirect interaction between ligand-activated PPARalpha and the TGF-beta-regulated Smad4 transcription factors. The full text of this article is available at http://www.circresaha.org.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456495     DOI: 10.1161/01.res.0000046017.96083.34

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  19 in total

1.  Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

Authors:  Daniel M Rotroff; Sonja S Pijut; Skylar W Marvel; John R Jack; Tammy M Havener; Aurora Pujol; Agatha Schluter; Gregory A Graf; Henry N Ginsberg; Hetal S Shah; He Gao; Mario-Luca Morieri; Alessandro Doria; Josyf C Mychaleckyi; Howard L McLeod; John B Buse; Michael J Wagner; Alison A Motsinger-Reif
Journal:  Clin Pharmacol Ther       Date:  2017-11-03       Impact factor: 6.875

2.  Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.

Authors:  Gani Oruqaj; Srikanth Karnati; Vijith Vijayan; Lakshmi Kanth Kotarkonda; Eistine Boateng; Wenming Zhang; Clemens Ruppert; Andreas Günther; Wei Shi; Eveline Baumgart-Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

3.  Nicotinamide mononucleotide (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation and anti-atherogenic effects.

Authors:  Tamas Kiss; Cory B Giles; Stefano Tarantini; Andriy Yabluchanskiy; Priya Balasubramanian; Tripti Gautam; Tamas Csipo; Ádám Nyúl-Tóth; Agnes Lipecz; Csaba Szabo; Eszter Farkas; Jonathan D Wren; Anna Csiszar; Zoltan Ungvari
Journal:  Geroscience       Date:  2019-08-28       Impact factor: 7.713

4.  HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells.

Authors:  So Youn Park; Jin Ung Bae; Ki Whan Hong; Chi Dae Kim
Journal:  Korean J Physiol Pharmacol       Date:  2011-04-30       Impact factor: 2.016

5.  Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.

Authors:  Yunpeng Ye; Sharon Bloch; Baogang Xu; Samuel Achilefu
Journal:  J Med Chem       Date:  2006-04-06       Impact factor: 7.446

6.  Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats.

Authors:  C De Ciuceis; F Amiri; M Iglarz; J S Cohn; R M Touyz; E L Schiffrin
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

7.  Chlorotyrosine promotes human aortic smooth muscle cell migration through increasing superoxide anion production and ERK1/2 activation.

Authors:  Hong Mu; Xinwen Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

8.  Nitrotyrosine promotes human aortic smooth muscle cell migration through oxidative stress and ERK1/2 activation.

Authors:  Hong Mu; Xinwen Wang; Peter Lin; Qizhi Yao; Changyi Chen
Journal:  Biochim Biophys Acta       Date:  2008-05-05

Review 9.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

10.  Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin.

Authors:  Philippe Lefebvre; Fanny Lalloyer; Eric Baugé; Michal Pawlak; Céline Gheeraert; Hélène Dehondt; Jonathan Vanhoutte; Eloise Woitrain; Nathalie Hennuyer; Claire Mazuy; Marie Bobowski-Gérard; Francesco Paolo Zummo; Bruno Derudas; Ann Driessen; Guy Hubens; Luisa Vonghia; Wilhelmus J Kwanten; Peter Michielsen; Thomas Vanwolleghem; Jérôme Eeckhoute; An Verrijken; Luc Van Gaal; Sven Francque; Bart Staels
Journal:  JCI Insight       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.